An interventional study of Multi-Component Nutritional Formula and matched placebo in Sarcopenia and Intrinsic Capacity, sponsored by National Yang Ming Chiao Tung University. Not yet recruiting at 1 site in Taiwan. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by National Yang Ming Chiao Tung University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 96 studies in Sarcopenia with a site in Taiwan — 30 open to participants now, 31 under way, none of them phase 3. Sarcopenia · Taiwan.
Among the 96 studies in Sarcopenia with a site in Taiwan, this one is the 37th largest by planned enrollment of the 67 interventional ones that give a count, is one of 10 that started in 2026, is one of 63 with no phase, reaches primary completion later than 18 of the 30 other live ones, and was the 95th registered.
1,330 studies on the registry are indexed under Sarcopenia; 419 are open to participants now.
Browse Sarcopenia studies →30 of the 96 studies in Sarcopenia with a site in Taiwan are open now. Recruiting first, the newest first:
Taipei Medical University Hospital · Sites in Taiwan
Ages 60+
Tzu Chi University · Sites in Taiwan
Ages 65–100 · Healthy volunteers
yueh chu wu · Sites in Taiwan
Ages 45–85
Valeria Chiu · Sites in Taiwan
Ages 18+ · Women only
National Health Research Institutes, Taiwan · Sites in Taiwan
Ages 40+ · Healthy volunteers
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 247 Sarcopenia studies recruiting now, 153 (62%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 65 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
96 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 10 started in 2026.
This study's planned enrollment of 70 is above the median of 60 across 856 interventional studies indexed under Sarcopenia.
Median enrollment 80 across the 67 interventional studies, 151 across the 29 observational. Of the 51 that completed or were terminated, 4 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 96 have an industry lead sponsor. The 10 most frequent:
National Yang Ming Chiao Tung University is the lead sponsor of 208 studies on the registry; 58 are open to participants now.
National Yang Ming Chiao Tung University has 1 study filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
7 of the studies in Sarcopenia with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07830472Taipei Medical University HospitalLower-Limb Rehabilitation Robot Training for Sarcopenia | 2026-12 |
| NCT02635022National Taiwan University HospitalFragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study | 2026-12 |
| NCT07815158National Yang Ming Chiao Tung UniversityMulti-Component Nutrition, Intrinsic Capacity, and Physical Function in Older Adults | 2026-12-15 |
| NCT07726758Tzu Chi UniversityThe Effectiveness of Squat Exercise for Improving Pre-Sarcopenia in Order Adults | 2026-12-31 |
| NCT07465393Valeria ChiuFacility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors | 2027-04-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 96 studies in Sarcopenia with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the effects of a 12-week multi-component nutritional formula on World Health Organization (WHO) Integrated Care for Older People (ICOPE) intrinsic capacity domains, physical function, and metabolic biomarkers in community-dwelling older adults. Besides, the investigators use standardized ICOPE Step 2 assessments, functional capacity scales, and metabolic biomarkers (including GDF-15, HOMA-IR, TyG index, LAP, and FIB-4) as outcome measures to validate whether the multi-component nutritional supplement could improve intrinsic capacity and health in older adults.
With aging, physiological functions and intrinsic capacity across multiple domains decline, leading to increased risks of sarcopenia, frailty, and metabolic dysfunction. The World Health Organization (WHO) introduced the Integrated Care for Older People (ICOPE) framework - covering locomotion, vitality, cognition, psychology, vision, and hearing - to promote healthy aging. This double-blind randomized controlled trial evaluates whether a 12-week intervention using an 18-component multi-component nutritional formula can improve ICOPE intrinsic capacity domains, physical function, and metabolic biomarkers in community-dwelling older adults. Through this trial, investigators aim to establish clinical evidence for nutritional strategies in managing age-related functional and metabolic declines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meets at least one of the following priority recruitment criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group receive the active 18-component multi-component nutritional formula daily for 12 consecutive weeks (84 days) while maintaining their routine diet and physical activity.
Dietary Supplement: Multi-Component Nutritional Formula
Participants in this group receive an appearance-, flavor-, and taste-matched placebo powder daily for 12 consecutive weeks (84 days) while maintaining their routine diet and physical activity.
Dietary Supplement: matched placebo
Daily oral consumption of the multi-component nutritional powder dissolved in warm water for 12 weeks. The formula contains muscle-anabolic proteins (whey protein, yeast protein, leucine), bone-supportive nutrients (MBP, coral calcium, vitamins D3/K2), and bioactive compounds (mulberry leaf extract, astragalus, grape seed extract, phosphatidylserine, fish oil, and lutein).
Daily oral consumption of the matched placebo powder dissolved in warm water for 12 weeks. The placebo is calorie-matched (within 10% caloric difference) but contains no active proteins, free amino acids, calcium/vitamin D3/K2 supplements, fish oil, or botanical extracts.
Change in Locomotion Measured by Short Physical Performance Battery (SPPB)
Assessed by the Short Physical Performance Battery (SPPB), covering balance, chair stand, and gait speed. Scores range from 0 to 12, where higher scores indicate better lower-extremity physical function.
Time frame: Baseline, Week 12
Change in 6-Meter Gait Speed
Measured by the 6-meter gait speed test in meters per second (m/s). Higher speed indicates better physical mobility
Time frame: Baseline, Week 12
Change in Handgrip Strength
Measured in kilograms (kg) using a handheld dynamometer on the dominant hand (maximum of two trials). Higher values indicate greater muscle strength.
Time frame: Baseline, Week 12
Change in Nutritional Status by MNA-SF
Assessed by the Mini Nutritional Assessment-Short Form (MNA-SF). Scores range from 0 to 14, where scores ≤11 indicate malnutrition risk and higher scores represent better nutritional status
Time frame: Baseline, Week 12
Change in Body Weight
Measured in kilograms (kg) under fasting conditions.
Time frame: Baseline, Week 12
Change in Calf Circumference
Measured in centimeters (cm) at the widest part of the calf. Higher values indicate greater muscle mass reserve.
Time frame: Baseline, Week 12
Change in Cognitive Function by MoCA
Assessed by the Montreal Cognitive Assessment (MoCA). Scores range from 0 to 30, with higher scores reflecting better global cognitive performance.
Time frame: Baseline, Week 12
Change in Depressive Symptoms by GDS-5
Assessed by the 5-item Geriatric Depression Scale (GDS-5). Scores range from 0 to 5, where higher scores indicate greater depressive symptoms (scores ≥2 suggest depression risk).
Time frame: Baseline, Week 12
Change in Visual Impairment Status
Evaluated based on WHO ICOPE Step 2 vision assessment criteria (classified as visual impairment: Yes or No).
Time frame: Baseline, Week 12
Change in Hearing Impairment Status
Evaluated using the whisper voice test based on WHO ICOPE Step 2 criteria (classified as hearing impairment: Yes or No).
Time frame: Baseline, Week 12
Change in Basic Activities of Daily Living by Barthel Index
Scores range from 0 to 100, where higher scores indicate greater independence in physical functioning and personal care.
Time frame: Baseline, Week 12
Change in Instrumental Activities of Daily Living by Lawton IADL Scale
Assessed using the Lawton Instrumental Activities of Daily Living (IADL) Scale, with scores ranging from 0 to 8, where higher scores indicate better ability to perform instrumental activities of daily living.
Time frame: Baseline, Week 12
Change in Frailty Status by Fried CHS Phenotype
Evaluated using the Fried Cardiovascular Health Study (CHS) criteria (0 to 5 criteria), categorizing participants as robust (0), pre-frail (1-2), or frail (3-5).
Time frame: Baseline, Week 12
Change in Clinical Frailty Scale (CFS)
Measured using the Clinical Frailty Scale (CFS), with scores ranging from 1 to 9, where higher scores indicate greater frailty and a worse outcome.
Time frame: Baseline, Week 12
Change in Quality of Life by SF-36 Health Survey
Assessed by the Short Form 36 (SF-36) questionnaire, evaluating physical and mental health component summary scores (scores 0-100, higher scores reflect better quality of life).
Time frame: Baseline, Week 12
Change in Skeletal Muscle Mass Index by Bioelectrical Impedance Analysis (BIA)
Measured using a multi-frequency InBody Bioelectrical Impedance Analysis (BIA) device. Skeletal Muscle Mass Index (SMI) is expressed in kg/m². Higher SMI values indicate greater skeletal muscle mass relative to height and a better outcome.
Time frame: Baseline, Week 12
Change in Visceral Fat Area by Bioelectrical Impedance Analysis
Measured using a multi-frequency InBody Bioelectrical Impedance Analysis (BIA) device. Visceral Fat Area (VFA) is expressed in cm². Higher VFA values indicate greater visceral adiposity and a worse outcome.
Time frame: Baseline, Week 12
Change in Body Fat Percentage by Bioelectrical Impedance Analysis
Measured using a multi-frequency InBody Bioelectrical Impedance Analysis (BIA) device. Body Fat Percentage is expressed as a percentage (%). Higher body fat percentage indicates a greater proportion of body fat and a worse outcome.
Time frame: Baseline, Week 12
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
calculated by Homeostatic Model Assessment for Insulin Resistance, HOMA-IR
Time frame: Baseline, Week 12
Change in Triglyceride-Glucose (TyG) Index
calculated by Triglyceride-Glucose Index, TyG index. Higher values indicate greater metabolic and insulin resistance risk.
Time frame: Baseline, Week 12
Change in Lipid Accumulation Product (LAP)
calculated by Lipid Accumulation Product, LAP. Reflects visceral adiposity.
Time frame: Baseline, Week 12
Change in Serum Growth Differentiation Factor-15 (GDF-15)
measured by serum Growth Differentiation Factor-15, GDF-15, as a circulating biomarker of biological aging and mitochondrial stress.
Time frame: Baseline, Week 12
Change in Fibrosis-4 (FIB-4) Index
calculated by Fibrosis-4 Index, FIB-4. Used to estimate hepatic steatosis-associated fibrosis risk.
Time frame: Baseline, Week 12
Change in Glycated Hemoglobin (HbA1c)
measured by Glycated Hemoglobin, HbA1c
Time frame: Baseline, Week 12
Change in High-Sensitivity C-Reactive Protein (hs-CRP)
Measured in mg/L as a circulating marker of systemic low-grade inflammation.
Time frame: Baseline, Week 12
Change in Serum 25-Hydroxyvitamin D [25(OH)D]
Measured in ng/mL to reflect nutritional vitamin D status
Time frame: Baseline, Week 12
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Dec 2026, 3 months later.
Of 494 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 35. This study's planned 3 months is below that.
Counting every sponsor, half of 505 studies reached it within 18 months; a quarter within 8 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Yang Ming Chiao Tung University →